Merck/Schering-Plough Zetia NDA
Executive Summary
Merck/Schering-Plough joint venture files NDA Dec. 27 for Zetia (ezetimibe) tablets for the reduction of elevated cholesterol. "Zetia is the first medicine to be submitted to the FDA for approval by Merck/Schering-Plough Pharmaceuticals," the joint venture notes. The product will be supported by three sales forces (1"The Pink Sheet" Dec. 17, 2001, p. 11)...
You may also be interested in...
Merck/Schering Zetia (Ezetimibe) Will Be Supported By Three Sales Forces
Merck will follow the Zocor model in launching Zetia (ezetimibe) into the cholesterol-lowering class by relying on separate sales forces and a co-promotion partner to establish the new product
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.